(Q45288661)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

title

Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

0 references

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

José J. Lucas

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Felix Hernandez

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Andrés Miguez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Marta Fernández-Nogales

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Silvia Ginés

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Esther Pérez-Navarro

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

publication date

16 June 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

published in

Human Molecular Genetics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

5040-5052

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Huntington's disease: from molecular pathogenesis to clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

GSK-3: tricks of the trade for a multi-tasking kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

A beta-arrestin 2 signaling complex mediates lithium action on behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Glycogen synthase kinase-3 is essential for β-arrestin-2 complex formation and lithium-sensitive behaviors in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

A dopamine D2 receptor-DISC1 protein complex may contribute to antipsychotic-like effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Regulation of glycogen synthase kinase-3 during bipolar mania treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

A critical appraisal of lithium's efficacy and effectiveness: the last 60 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

A feasibility and tolerability study of lithium in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

GSK3 inhibitors: development and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Design of glycogen synthase kinase-3 inhibitors: an overview on recent advancements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Mutant huntingtin alters Tau phosphorylation and subcellular distribution

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Neuronal apoptosis and reversible motor deficit in dominant-negative GSK-3 conditional transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Neuronal apoptosis and motor deficits in mice with genetic inhibition of GSK-3 are Fas-dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Anesthesia and post-mortem interval profoundly influence the regulatory serine phosphorylation of glycogen synthase kinase-3 in mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

The GSK3 hypothesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Pharmacological inhibitors of glycogen synthase kinase 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Effects of DNMT1 and HDAC inhibitors on gene-specific methylation reprogramming during porcine somatic cell nuclear transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-κΒ and p70s6k, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Activator or inhibitor? GSK-3 as a new drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Huntington's disease is a four-repeat tauopathy with tau nuclear rods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Glycogen synthase kinase-3beta phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FHMG%2FDDV224

21 January 2018

Identifiers

DOI

10.1093/HMG/DDV224

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26082469%20AND%20SRC:MED&resulttype=core&format=json

release_hgnm674rmfaetpcrhijjkdl5d4

17 February 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hgnm674rmfaetpcrhijjkdl5d4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference